Cargando…

Frequency of De Novo Hepatocellular Carcinoma after Direct-acting Antiviral Therapy for Chronic Hepatitis C: A Prospective Follow-up

BACKGROUND: Chronic hepatitis C (CHC) management has changed tremendously after direct-acting antivirals (DAAs) availability. Sustained virological response (SVR) has improved significantly, but one of the major concerns is the chances of de novo hepatocellular carcinoma (HCC) development after DAAs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rasool, Shahid, Hanif, Sofia, Ahmad, Aneeqa, Shafqat, Umair, Babar, Ahmad Nawaz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Jaypee Brothers Medical Publishers 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10028701/ https://www.ncbi.nlm.nih.gov/pubmed/36959987 http://dx.doi.org/10.5005/jp-journals-10018-1383

Ejemplares similares

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
por: Kuftinec, Gabriela, et al.
Publicado: (2018)

Impact of direct-acting antiviral therapy for hepatitis C–related hepatocellular carcinoma
por: Lin, Wei-Chen, et al.
Publicado: (2020)

Direct-acting antivirals for hepatitis C virus-infected patients with hepatocellular carcinoma
por: Tajiri, Kazuto, et al.
Publicado: (2022)

Outcomes and Follow-Up after Hepatitis C Eradication with Direct-Acting Antivirals
por: Lynch, Erica Nicola, et al.
Publicado: (2023)

Hepatitis C Virus and Hepatocellular Carcinoma: Pathogenetic Mechanisms and Impact of Direct-Acting Antivirals
por: Schietroma, Ivan, et al.
Publicado: (2018)

The use of Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients with Hepatocellular Carcinoma
por: Economides, Minas, et al.
Publicado: (2017)

Impact of Direct Acting Antivirals on Survival in Patients with Chronic Hepatitis C and Hepatocellular Carcinoma
por: Kamp, William M., et al.
Publicado: (2019)

Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C
por: Tse, Chung Sang, et al.
Publicado: (2020)

Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022)

Hepatocellular carcinoma recurrence after directly acting antivirals for chronic hepatitis C: a 2-year follow-up study
por: Kamal, Ahmed, et al.
Publicado: (2021)

Hepatocellular carcinoma after direct‐acting antiviral drug treatment in patients with hepatitis C virus
por: Kogiso, Tomomi, et al.
Publicado: (2018)

Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-infected Patients Treated with Direct-acting Antivirals
por: Syed, Taseen, et al.
Publicado: (2018)

Direct-Acting Antiviral Therapy and Risk of Hepatocellular Carcinoma Recurrence in Patients with Chronic Hepatitis C
por: Lee, Chang Hun, et al.
Publicado: (2021)

Hepatic fibrosis changes in patients with chronic hepatitis C infection who respond to direct-acting antivirals
por: Alswat, Khalid, et al.
Publicado: (2022)

Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
por: Westermann, Claudia, et al.
Publicado: (2021)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
por: Karayiannis, Peter
Publicado: (2012)

Direct-acting antiviral retreatment patterns for hepatitis C
por: Hasan, Shaquib Al, et al.
Publicado: (2022)

Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows
por: Guarino, Maria, et al.
Publicado: (2018)

Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals
por: Lee, Hye Won, et al.
Publicado: (2020)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
por: Kwan, Byung Soo, et al.
Publicado: (2021)

Multimodal Treatment of Hepatocellular Carcinoma in Patients With Hepatitis C Virus Infection Treated With Direct-Acting Antivirals
por: Mercan-Stanciu, Adriana, et al.
Publicado: (2022)

Is direct-acting antiviral treatment beneficial or harmful for patients with hepatitis C virus-related hepatocellular carcinoma?
por: Lee, Hye Won
Publicado: (2022)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
por: Leal, Cassia, et al.
Publicado: (2023)

Direct-Acting Antivirals Reduce the De Novo Development of Esophageal Varices in Patients with Hepatitis C Virus Related Liver Cirrhosis
por: Hsieh, Yung-Yu, et al.
Publicado: (2023)

The frequency of occurrence of Hepatocellular Carcinoma after direct antiviral therapy in Hepatitis C virus patients
por: Aziz, Bilal, et al.
Publicado: (2019)

Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients
por: Fouad, Magdy, et al.
Publicado: (2021)

Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?
por: Huang, Chung-Feng, et al.
Publicado: (2019)

Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection
por: Sung, Pil Soo, et al.
Publicado: (2021)

Hepatocellular carcinoma after direct-acting antiviral hepatitis C virus therapy: A debate near the end
por: Muzica, Cristina Maria, et al.
Publicado: (2020)

Features of patients who developed hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C Virus
por: Mawatari, Seiichi, et al.
Publicado: (2022)

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
por: Lee, Shou-Wu, et al.
Publicado: (2022)

Alterations in Hepatocellular Carcinoma-Specific Immune Responses Following Hepatitis C Virus Elimination by Direct-Acting Antivirals
por: Li, Shihui, et al.
Publicado: (2022)

Psychiatric treatment considerations with direct acting antivirals in hepatitis C
por: Sockalingam, Sanjeev, et al.
Publicado: (2013)

Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals
por: Ahmed, Asma, et al.
Publicado: (2015)

Economic Evaluation of Direct-Acting Antivirals for Hepatitis C in Norway
por: Wisløff, Torbjørn, et al.
Publicado: (2018)

Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
por: McGlynn, Elizabeth A., et al.
Publicado: (2019)

Reduced work absenteeism in patients with hepatitis C treated with second‐generation direct‐acting antivirals
por: Lindgren, Peter, et al.
Publicado: (2020)

Direct-Acting Antiviral Drugs and Occurrence of Hepatocellular Carcinoma: Unjust or Oppressed
por: Hassany, Sahar M, et al.
Publicado: (2020)

Impact of Drug Use Policy on the Appropriate Use of Direct Acting Antiviral Agents for Hepatitis C in Saudi Arabia
por: Alotaibi, Ahmed Saqer, et al.
Publicado: (2021)

Neuropsychiatric performance and treatment of hepatitis C with direct-acting antivirals: a prospective study
por: Volpato, Sofia, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0so1kfkdge8ots9u0dmbki4ssl